Literature DB >> 12172743

Analysis of underlying diseases and prognosis factors associated with Pneumocystis carinii pneumonia in immunocompromised HIV-negative patients.

F Roblot1, C Godet, G Le Moal, B Garo, M Faouzi Souala, M Dary, L De Gentile, J A Gandji, Y Guimard, C Lacroix, P Roblot, B Becq-Giraudon.   

Abstract

The aim of this retrospective study was to determine the underlying diseases associated with Pneumocystis carinii pneumonia (PCP) in immunocompromised HIV-negative patients and to identify prognosis factors in this population. One hundred three cases of PCP were diagnosed over a 5-year period. Diagnosis was established on the basis of clinical features and by detection of Pneumocystis carinii cysts in bronchoalveolar lavage fluid. Underlying diseases comprised hematologic malignancies (n=60; 58%), inflammatory diseases (n=27; 26%), and solid tumors (n=18; 17.5%); 9 (8%) patients were solid organ transplant recipients. Seventy-one (69%) patients received cytotoxic drugs, 57 (55%) were treated with long-term corticotherapy, and 15 (14.7%) underwent bone marrow transplantation. Fifty-eight (56%) patients were admitted to the intensive care unit, and 52 (41%) required mechanical ventilation. Thirty-nine (38%) patients died of PCP; data from these patients were compared with those from surviving patients. The following factors were associated with a poor prognosis: high respiratory rate (P=0.005), high pulse rate (P=0.0003), elevated C-reactive protein (P=0.01), elevated serum lactate dehydrogenase level (P=0.02), and mechanical ventilation (OR, 14.4; 95%CI, 5-50). The results suggest that PCP can occur during the course of many immunosuppressive diseases, particularly various hematologic malignancies. The diagnosis of PCP should be considered more frequently and advocated earlier in immunocompromised HIV-negative patients, since prompt diagnosis may improve the prognosis of these patients.

Entities:  

Mesh:

Year:  2002        PMID: 12172743     DOI: 10.1007/s10096-002-0758-5

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  55 in total

1.  Severe pneumonia in the elderly: a multivariate analysis of risk factors.

Authors:  Wei Li; Cheng Ding; Shaojun Yin
Journal:  Int J Clin Exp Med       Date:  2015-08-15

Review 2.  Cavitary pulmonary disease.

Authors:  L Beth Gadkowski; Jason E Stout
Journal:  Clin Microbiol Rev       Date:  2008-04       Impact factor: 26.132

3.  Underlying renal insufficiency: the pivotal risk factor for Pneumocystis jirovecii pneumonia in immunosuppressed patients with non-transplant glomerular disease.

Authors:  Wen-Ling Ye; Nan Tang; Yu-Bing Wen; Hang Li; Min-Xi Li; Bin Du; Xue-Mei Li
Journal:  Int Urol Nephrol       Date:  2016-06-28       Impact factor: 2.370

Review 4.  Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients.

Authors:  Anat Stern; Hefziba Green; Mical Paul; Liat Vidal; Leonard Leibovici
Journal:  Cochrane Database Syst Rev       Date:  2014-10-01

5.  Pneumocystosis: a network survey in the Paris area 2003-2008.

Authors:  D Magne; A Angoulvant; F Botterel; C Bouges-Michel; M-E Bougnoux; P Bouree; C Chochillon; M Cornet; E Dannaoui; A Fekkar; G Galeazzi; H Yera; C Sarfati; P Roux
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-01-13       Impact factor: 3.267

6.  Characterization of Pneumocystis jirovecii pneumonia at three tertiary comprehensive hospitals in southern China.

Authors:  Yan-Hui Chen; Xue-Yao Fang; Yue-Ting Li; Yan-Ling Liu; Ya-Ping Hang; Yan-Ping Xiao; Xing-Wei Cao; Qiao-Shi Zhong; Long-Hua Hu
Journal:  Braz J Microbiol       Date:  2020-05-03       Impact factor: 2.476

7.  Validation of the MycAssay Pneumocystis kit for detection of Pneumocystis jirovecii in bronchoalveolar lavage specimens by comparison to a laboratory standard of direct immunofluorescence microscopy, real-time PCR, or conventional PCR.

Authors:  Lisa R McTaggart; Nancy L Wengenack; Susan E Richardson
Journal:  J Clin Microbiol       Date:  2012-03-14       Impact factor: 5.948

8.  Development and evaluation of a real-time PCR assay for detection of Pneumocystis jirovecii on the fully automated BD MAX platform.

Authors:  Alexander H Dalpke; Marjeta Hofko; Stefan Zimmermann
Journal:  J Clin Microbiol       Date:  2013-05-15       Impact factor: 5.948

9.  Impact of HIV Infection Status on Interpretation of Quantitative PCR for Detection of Pneumocystis jirovecii.

Authors:  M Louis; J Guitard; M Jodar; T Ancelle; D Magne; O Lascols; C Hennequin
Journal:  J Clin Microbiol       Date:  2015-10-14       Impact factor: 5.948

Review 10.  Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients.

Authors:  Martin Rodriguez; Jay A Fishman
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.